Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
The DOI matches its Crossref record; 370 of the 370 references it cites were found in a registry or an index.
Abstract
Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a machine-learning method, and a limited update to October 2016 was done. Clinical outcomes evaluated were fractures and adverse events. This guideline focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis. Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence). Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence). Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low-quality evidence). Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate-quality evidence). Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected trial reports were cited in nine effectiveness reviews and clinical guidelines (one published in Scotland, the others in the USA), for stroke,49 fracture prevention50–55 and fall and injury prevention.56”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“The updated 2017 American College of Physicians’ guidelines55 (74 citations, October 2018) includes two of the affected trial reports on 2.5 mg daily risedronate13 16 in its overview of the evidence for the use of risedronate from the AHRQ review,54 but does not discuss the specific issue of the lower dose of risedronate.”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“Fracture risk approximately doubles with every SD T-score reduction.137,138”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [138]
Citations
Cites
9 retracted
Sato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2005) · Cerebrovascular Diseases · doi:10.1159/000087203 · Cited by 410
RetractedWimalawansa, S. J. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00029-1 · Cited by 186
RetractedIshida, Y., & Kawai, S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.019 · Cited by 132
RetractedSato, Y., Manabe, S., Kuno, H., & Oizumi, K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.1.64 · Cited by 131
Retracted(2007) · Neurology · doi:10.1212/01.wnl.0000257089.50476.92 · Cited by 90 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedSato, Y., Kanoko, T., Satoh, K., & Iwamoto, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1737 · Cited by 69 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetracted(2003) · Neurology · doi:10.1212/01.wnl.0000078892.24356.90 · Cited by 51
RetractedSato, Y., Kuno, H., Kaji, M., Saruwatari, N., & Oizumi, K. (1999) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199909000-00008 · Cited by 37
RetractedAnti-Fracture Efficacy of Risedronic Acid in Men: A Meta-Analysis of Randomized Controlled Trials
Zhong, Z., & Chen, J. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929050-00007 · Cited by 30 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Research works printed but not linked: 25
- Bonnick S, 1998, Bone, 23, S476
- 10.1210/jcem.85.2.6393 · doi:10.1210/jcem.85.2.6393 · Paper page
- 10.1185/030079903125002009 · DOI · Paper page
- McClung M, 1998, Osteoporos Int, 8, 111
- Chao M, 2013, Pak J Med Sci, 29, 1381
- Lippuner K, 2013, Osteoporosis Int, 24, S39
- Palacios S, 2013, Osteoporosis Int, 24, S299
- Papapoulos S, 2013, Osteoporosis Int, 24, S45
- 10.1359/jbmr.2003.18.1.9 · DOI · Paper page
- 10.1210/jcem.85.9.6836 · doi:10.1210/jcem.85.9.6836 · Paper page
- Adachi JD, 1996, J Rheumatol, 23, 995
- Aloia JF, 1985, J Lab Clin Med, 106, 630
- Caniggia A, 1984, Acta Vitaminol Enzymol, 6, 117
- Geusens P, 1986, Bone Miner, 1, 347
- Jensen GF, 1985, Clin Orthop Relat Res, 215
- Menczel J, 1994, Clin Orthop Relat Res, 241
- Orimo H, 1987, Bone Miner, 3, 47
- Muscoso E, 2004, Eur Rev Med Pharmacol Sci, 8, 97
- Migliore A, 2013, Eur Rev Med Pharmacol Sci, 17, 658
- Almăşan HA, 2011, Rom J Morphol Embryol, 52, 1233
- 10.1056/nejmoa011807 · DOI · Paper page
- Krohn K, 2014, Osteoporosis Int, 25, S61, 10.1007/s00198-013-2525-0 · DOI
- 10.1210/jcem.87.3.8325 · doi:10.1210/jcem.87.3.8325 · Paper page
- Zheng S, 2003, Chin Med J (Engl), 116, 1127
- Liu JL, 2004, Chin Med J (Engl), 117, 1029
Cited by
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Wu, A.-M., Bisignano, C., James, S. L., Abady, G. G., Abedi, A., Abu-Gharbieh, E., Alhassan, R. K., Alipour, V., Arabloo, J., Asaad, M., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00172-0 · Cited by 1,291
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
Osteoporosis: A Review of Treatment Options.
Tu, K. N., Lie, J. D., Wan, C. K. V., Cameron, M., Austel, A. G., Nguyen, J. K., Van, K., & Hyun, D. (2018) · PubMed Central · Cited by 735
Ensrud, K. E., & Crandall, C. J. (2017) · Annals of Internal Medicine · doi:10.7326/aitc201708010 · Cited by 726
Johnston, C. B., & Dagar, M. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.06.004 · Cited by 615
Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review
Margiana, R., Markov, A., Zekiy, A. O., Hamza, M. U., Al-Dabbagh, K. A., Al-Zubaidi, S. H., Hameed, N. M., Ahmad, I., Sivaraman, R., Kzar, H. H., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03054-0 · Cited by 429
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Osteoporosis: current concepts
Akkawi, I., & Zmerly, H. (2018) · Joints · doi:10.1055/s-0038-1660790 · Cited by 368
The Prevalence of Osteoporosis in China, a Nationwide, Multicenter DXA Survey
Zeng, Q., Li, N., Wang, Q., Feng, J., Sun, D., Zhang, Q., Huang, J., Wen, Q., Hu, R., Wang, L., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3757 · Cited by 348
Guidelines for the management of osteoporosis and fragility fractures
Nuti, R., Brandi, M. L., Checchia, G., Di Munno, O., Dominguez, L., Falaschi, P., Fiore, C. E., Iolascon, G., Maggi, S., Michieli, R., et al. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1874-2 · Cited by 328
Management of Menopausal Symptoms: A Review
Crandall, C. J., Mehta, J. M., & Manson, J. E. (2023) · JAMA · doi:10.1001/jama.2022.24140 · Cited by 316
Estrogen therapy for osteoporosis in the modern era
Levin, V. A., Jiang, X., & Kagan, R. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4414-z · Cited by 258
“Conversely, the American College of Physicians (ACP) supported against HT in their clinical practice guideline for the treatment of osteoporosis in women, stating that highquality evidence from the WHI showed that HTwas associated with increased risk for venous thromboembolic (VTE), cerebrovascular events, invasive br…”
BackgroundOsteoporosis: Pathophysiology and therapeutic options
Föger‐Samwald, U., Dovjak, P., Azizi-Semrad, U., Kerschan‐Schindl, K., & Pietschmann, P. (2020) · EXCLI journal · doi:10.17179/excli2020-2591 · Cited by 257
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
Conley, R. B., Adib, G., Adler, R. A., Åkesson, K. E., Alexander, I. M., Amenta, K. C., Blank, R. D., Brox, W. T., Carmody, E. E., Chapman-Novakofski, K., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3877 · Cited by 242
Exercise, brain plasticity, and depression
Zhao, J., Jiang, W., Wang, X., Cai, Z., Liu, Z., & Liu, G. (2020) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13385 · Cited by 241
Qaseem, A., Hicks, L. A., Etxeandia-Ikobaltzeta, I., Shamliyan, T., Cooney, T. G., & Clinical Guidelines Committee of the American College of Physicians (2023) · Annals of Internal Medicine · doi:10.7326/m22-1034 · Cited by 241
Self-citationRecent Advances of Osterix Transcription Factor in Osteoblast Differentiation and Bone Formation
Liu, Q., Li, M., Wang, S., Xiao, Z., Xiong, Y., & Wang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.601224 · Cited by 235
Black, D. M., Bauer, D. C., Vittinghoff, E., Lui, L.-Y., Grauer, A., Marin, F., Khosla, S., de Papp, A., Mitlak, B., Cauley, J. A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30159-5 · Cited by 228
Secondary Osteoporosis and Metabolic Bone Diseases
Sobh, M., Abdalbary, M., Elnagar, S., Nagy, E., Elshabrawy, N. A., Abdelsalam, M., Asadipooya, K., & El-Husseini, A. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092382 · Cited by 191
Insights and implications of sexual dimorphism in osteoporosis
Zhang, Y., Xie, N., Sun, X., Nice, E. C., Liou, Y., Huang, C., Zhu, H., & Shen, Z. (2024) · Bone Research · doi:10.1038/s41413-023-00306-4 · Cited by 184
“352 In addition to the therapeutic effects of alendronate in treating male patients with primary osteoporosis, the agent is effective for males with a high risk of developing fractures.”
BackgroundMazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Fink, H. A., MacDonald, R. H., Forte, M. L., Rosebush, C. E., Ensrud, K. E., Schousboe, J. T., Nelson, V. A., Ullman, K. E., Butler, M. E., Olson, C. M., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0533 · Cited by 170
Cotts, K. G., & Cifu, A. S. (2018) · JAMA · doi:10.1001/jama.2017.21995 · Cited by 166
Gut Microbiome Reveals Specific Dysbiosis in Primary Osteoporosis
Xu, Z., Xie, Z., Sun, J., Huang, S., Chen, Y., Li, C., Sun, X., Xia, B., Tian, L., Guo, C., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00160 · Cited by 164
“Osteoporotic fracture refers to a fracture that occurs during minor trauma or daily activities, which is a serious consequence of osteoporosis (Qaseem et al., 2017), one of the main causes of disability and death among elderly patients (Black and Rosen, 2016).”
BackgroundShort-course systemic corticosteroids in asthma: striking the balance between efficacy and safety
Price, D. B., Castro, M., BOURDIN, A. A., Fucile, S., & Altman, P. (2020) · European Respiratory Review · doi:10.1183/16000617.0151-2019 · Cited by 157
Di Nardo, G., Villa, M. P., Conti, L., Ranucci, G., Pacchiarotti, C., Principessa, L., Raucci, U., & Parisi, P. (2019) · Nutrients · doi:10.3390/nu11071588 · Cited by 156
Pharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based - Expert Opinion
Migliorini, F., Colarossi, G., Baroncini, A., Eschweiler, J., Tingart, M., & Maffulli, N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1851192 · Cited by 155
Pharmacological Therapy of Osteoporosis: A Systematic Current Review of Literature
Pavone, V., Testa, G., Giardina, S. M. C., Vescio, A., Restivo, D. A., & Sessa, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00803 · Cited by 154
“These drugs are typically used in combination with conjugated estrogens (Qaseem et al., 2017).”
BackgroundCurrent use of bone turnover markers in the management of osteoporosis
Brown, J. P., Don-Wauchope, A., Douville, P., Albert, C., & Vasikaran, S. D. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.09.002 · Cited by 153
Deardorff, W. J., Cenzer, I. S., Nguyen, B., & Lee, S. J. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.6745 · Cited by 146
Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors
Santen, R. J., Stuenkel, C. A., Davis, S. R., Pinkerton, J. V., Gompel, A., & Lumsden, M. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01138 · Cited by 125
Impacts of Psychological Stress on Osteoporosis: Clinical Implications and Treatment Interactions
Kelly, R. R., McDonald, L. T., Jensen, N. R., Sidles, S. J., & LaRue, A. C. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00200 · Cited by 115
Use of dienogest in endometriosis: a narrative literature review and expert commentary
Murji, A., Biberoğlu, K., Leng, J., Mueller, M. D., Römer, T., Vignali, M., & Yarmolinskaya, M. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1744120 · Cited by 116
Adams, A. L., Fischer, H. J., Kopperdahl, D. L., Lee, D. C., Black, D. M., Bouxsein, M., Fatemi, S., Khosla, S., ORWOLL, E. S., Siris, E. S., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3423 · Cited by 125
“We report the hip BMD T-score for direct comparison with BCT and also the widely used((34)) lowest BMD T-score across both the hip (femoral neck or total hip) and spine (“hip/spine” BMD T-score).”
MethodKrueger, D. C., Tanner, S. B., Szalat, A., Malabanan, A. O., Prout, T. M., Lau, A., Rosen, H. N., & Shuhart, C. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101437 · Cited by 124
Artificial intelligence, osteoporosis and fragility fractures
Ferizi, U., Honig, S., & Chang, G. A. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000607 · Cited by 120
Lyu, H., Jundi, B., Xu, C. Q., Tedeschi, S. K., Yoshida, K., Zhao, S. S., Nigwekar, S. U., Leder, B. Z., & Solomon, D. H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02236 · Cited by 118
Osteoporosis therapies and their mechanisms of action (Review)
Kim, B., Cho, Y., & Lim, W. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10815 · Cited by 120
Iseri, K., Watanabe, M., Yoshikawa, H., 三井, 久., Endo, T., Yamamoto, Y., Iyoda, M., Ryu, K., Inaba, T., & Shibata, T. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3676 · Cited by 112
“Bisphosphonates, known as antiresorptive agents, are widely used for the treatment of primary osteoporosis, glucocorticoidinduced osteoporosis, and other skeletal disorders.((22,23)) Moreover, the value of bisphosphonate treatment for osteoporosis in patients with CKD stages 1 to 3 has already been clarified.”
BackgroundAdvances in the Fabrication of Scaffold and 3D Printing of Biomimetic Bone Graft
Bisht, B., Hope, A., Mukherjee, A., & Paul, M. K. (2021) · Annals of Biomedical Engineering · doi:10.1007/s10439-021-02752-9 · Cited by 111
Clinical Update on Osteoporosis
Anthamatten, A., & Parish, A. L. (2019) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.12954 · Cited by 108
Long noncoding RNAs: a missing link in osteoporosis
da Silva, A. M., Moura, S. R., Teixeira, J. H., Barbosa, M. A., Santos, S. G., & Almeida, M. I. (2019) · Bone Research · doi:10.1038/s41413-019-0048-9 · Cited by 108
Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Candelas, G., et al. (2018) · Reumatología Clínica · doi:10.1016/j.reuma.2018.09.004 · Cited by 104
Shuhart, C., Cheung, A. M., Gill, R. S., Gani, L. U., Goel, H., & Szalat, A. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101435 · Cited by 104
Bone Health Optimization: Beyond Own the Bone
Anderson, P. A., Jeray, K. J., Lane, J. M., & Binkley, N. (2019) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.18.01229 · Cited by 99
Takusari, E., Sakata, K., Hashimoto, T., Fukushima, Y., Nakamura, T., & Orimo, H. (2020) · JBMR Plus · doi:10.1002/jbm4.10428 · Cited by 99
EAA clinical guideline on management of bone health in the andrological outpatient clinic
Rochira, V., Antonio, L., & Vanderschueren, D. (2018) · Andrology · doi:10.1111/andr.12470 · Cited by 89
Bisphosphonates for Postmenopausal Osteoporosis
Ensrud, K. E., & Crandall, C. J. (2019) · JAMA · doi:10.1001/jama.2019.15781 · Cited by 92
Systemic therapy of MSCs in bone regeneration: a systematic review and meta-analysis
Fu, J., Wang, Y., Jiang, Y., Du, J., Xu, J., & Liu, Y. F. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02456-w · Cited by 91
Muruganandan, S., Ionescu, A. M., & Sinal, C. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072277 · Cited by 90
“Similarly, the use of teriparatide is associated with several untoward effects including upper gastrointestinal symptoms, hypercalcemia, renal side effects and hypercalciuria [82].”
BackgroundInfluentialWang, X., Yang, S., He, G., & Xie, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1191501 · Cited by 87
Mechanistic Insights and Therapeutic Strategies in Osteoporosis: A Comprehensive Review
Elahmer, N. R., Wong, S. K., Mohamed, N., Alias, E., Chin, K., & Muhammad, N. (2024) · Biomedicines · doi:10.3390/biomedicines12081635 · Cited by 88
“SERMs raise the risk of thromboembolic disorder, muscular spasms, and cerebrovascular accident [88].”
BackgroundThe m6A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG
Chen, L.-S., Zhang, M., Chen, P., Xiong, X., Liu, P., Wang, H., Wang, J., & Shen, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00756-8 · Cited by 84
FRAX-based intervention and assessment thresholds in seven Latin American countries
Clark, P., Denova‐Gutiérrez, E., Zerbini, C. A. F., Sánchez, A., Messina, O. D., Jaller, J. J., Campusano, C., Orces, C. H., Riera, G., Johansson, H., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4341-4 · Cited by 79
Osteoporosis Screening: Applied Methods and Technological Trends.
de Oliveira, M. D., Moraes, R., Castanha, E., Prevedello, A. S., Filho, J. V., Bussolaro, F. A., & Cava, D. G. (2022) · Medical Engineering and Physics · doi:10.1016/j.medengphy.2022.103887 · Cited by 58
Adler, R. A. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.05.007 · Cited by 78
Addressing unmeasured confounding in comparative observational research
Zhang, X., Faries, D. E., Li, H., Stamey, J. D., & Imbens, G. W. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4394 · Cited by 74
Risk of Subsequent Fractures in Postmenopausal Women After Nontraumatic vs Traumatic Fractures
Crandall, C. J., Larson, J. C., LaCroix, A. Z., Robbins, J. A., Wactawski‐Wende, J., Johnson, K., Sattari, M., Stone, K. L., Weitlauf, J. C., Gure, T. R., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2617 · Cited by 73
The “Three in One” Bone Repair Strategy for Osteoporotic Fractures
Chen, X., Hu, Y., Geng, Z., & Su, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.910602 · Cited by 71
Singer, A. J., McClung, M. R., Tran, O., Morrow, C. D., Goldstein, S., Kagan, R., McDermott, M., & Yehoshua, A. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01229-7 · Cited by 71
“Globally, women over the age of 50 have a 9.8 to 22.8% lifetime risk of fragility fractures and fractures will occur among 1 in 3 [3].”
BackgroundInfluentialStigliano, S., Waldthaler, A., Martínez-Moneo, E., Lionetto, L., Robinson, S. M., Malvik, M., Hedström, A., Kaczka, A., Scholdei, M., Haas, S., et al. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/s41424-018-0066-8 · Cited by 71
Cosman, F. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0596 · Cited by 71
The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women
Sánchez‐Rodríguez, D., Bergmann, P., Body, J., Cavalier, E., Gielen, E., Goemaere, S., Lapauw, B., Laurent, M. R., Rozenberg, S., Honvo, G., et al. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.05.006 · Cited by 71
“Three MA [30,41,52], 6 SR [99,102–106], 14 guidelines [1,110–112, 115 , 118, 120 ,121,123,124,127,128,132,133], and 22 articles by manual search [139,140,145,147, 155– 163 , 166,195,199– 201 Q4.”
BackgroundDiagnosis and Treatment of Osteoporosis: What Orthopaedic Surgeons Need to Know
Matzkin, E. G., DeMaio, M., Charles, J. F., & Franklin, C. C. (2019) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-18-00600 · Cited by 69
Your results may vary: the imprecision of medical measurements
McCormack, J. P., & Holmes, D. T. (2020) · BMJ · doi:10.1136/bmj.m149 · Cited by 68
Three Classes of Antioxidant Defense Systems and the Development of Postmenopausal Osteoporosis
Yang, K., Cao, F., Xue, Y., Tao, L., & Zhu, Y. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.840293 · Cited by 66
Hanga-Fărcaș, A., Miere, F. G., Filip, G. A., Clichici, S. V., Fritea, L., Vicaș, L. G., Marian, E., Pallag, A., Jurca, T., Filip, S. M., et al. (2023) · Plants · doi:10.3390/plants12102055 · Cited by 66
Timed up-and-go test is a useful predictor of fracture incidence
Jeong, S., Shin, D. W., Han, K., Jung, J., Chun, S., Jung, H., & Son, K. Y. (2019) · Bone · doi:10.1016/j.bone.2019.07.018 · Cited by 65
Muscle density is an independent risk factor of second hip fracture: a prospective cohort study
Wang, L., Yin, L., Yang, M., Ge, Y., Liu, Y., Su, Y., Guo, Z., Yan, D., Xu, Z., Huang, P., et al. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12996 · Cited by 65
Nayak, S., & Greenspan, S. L. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3437 · Cited by 66
O’Reilly, N., Nelson, H. D., Conry, J. M., Frost, J., Gregory, K. D., Kendig, S. M., PHIPPS, M. G., Salganicoff, A. N., Ramos, D., Zahn, C. M., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0595 · Cited by 64
“Although, like the previous IOM panel, the WPSI bases its guidance on a certain threshold of supportive evidence, the recommendation presented here could be translated to a weak-level recommendation on the basis of the American College of Physicians guideline grading system, adopted from the GRADE (Grading of Recommen…”
MethodSelf-citationWang, J., Zhang, X., Zhang, L., Liu, Y., Wang, G., Zhang, H. P., Kang, D. Y., Kang, D. Y., Oliver, B. G. G., Wan, H. J., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.09.029 · Cited by 64
Yedavally-Yellayi, S., Ho, A. M., & Patalinghug, E. (2018) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2018.10.014 · Cited by 63
Avenell, A., Stewart, F., Grey, A., Gamble, G., & Bolland, M. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031909 · Cited by 59
“In eight cases, 58–65 affected trial reports contributed to the rationale for undertaking further RCTs.”
BackgroundUtility of DXA for monitoring, technical aspects of DXA BMD measurement and precision testing
CAREY, J. J., & Delaney, M. F. (2017) · Bone · doi:10.1016/j.bone.2017.05.021 · Cited by 59
Xie, Q., Chen, Y., Hu, Y., Zeng, F., Wang, P., Xu, L., Wu, J., Li, J., Zhu, J. F., Xiang, M., et al. (2022) · BMC Medical Imaging · doi:10.1186/s12880-022-00868-5 · Cited by 57
Qayoom, I., Teotia, A. K., & Kumar, A. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b01327 · Cited by 57
Quality of English-language videos available on YouTube as a source of information on osteoporosis
Önder, M. E., Önder, Ç. E., & Zengin, O. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01064-2 · Cited by 57
Bone Health Optimization in Orthopaedic Surgery
Kadri, A., Binkley, N., Hare, K. J., & Anderson, P. A. (2020) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.19.00999 · Cited by 55
Gao, Y., Liu, X., Gu, Y., Song, D., Ding, M., Liao, L., Wang, J., Ni, J., & He, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.688269 · Cited by 55
Parvaneh, M., Karimi, G., Jamaluddin, R., NG, A. M. H., Ibrahim, Z., & Muhammad, S. I. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s169223 · Cited by 47
Li, J., Yao, Z., Liu, X. Z., Duan, R., Yi, X., Ayoub, A., Sanders, J. O., Mesfin, A., Xing, L., & Boyce, B. F. (2023) · Nature Communications · doi:10.1038/s41467-023-35801-z · Cited by 53
Plain vitamin D or active vitamin D in the treatment of osteoporosis: where do we stand today?
Ringe, J. D. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00842-0 · Cited by 52
Hussain, A., Tripathi, A., Pieczonka, C. M., Cope, D. G., McNatty, A. L., Logothetis, C. J., & Guise, T. A. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-00296-y · Cited by 51
Schousboe, J. T., Lix, L. M., Morin, S. N., Derkatch, S., Bryanton, M., Alhrbi, M., & Leslie, W. D. (2019) · Bone · doi:10.1016/j.bone.2019.01.009 · Cited by 51
Medical treatment of osteoporosis
Palacios, S. (2021) · Climacteric · doi:10.1080/13697137.2021.1951697 · Cited by 51
“Osteoporosis treatment options: summary of recommendations [1,2,28,29].”
Shao, X., Fu, X., Yang, J., Sui, W., Li, S., Yang, W., Lin, X., Zhang, Y., Jia, M., Liu, W., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00531-5 · Cited by 50
Tratamiento de la osteoporosis
Nogués, X., & Martínez-Laguna, D. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.10.019 · Cited by 49
Zhang, D., Zhang, S., Jiang, K., Li, T., & Yan, C. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113113 · Cited by 49
Pathophysiological mechanism of acute bone loss after fracture
Zheng, X.-Q., Huang, J., Lin, J., & Song, C. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.08.019 · Cited by 49
“64 The most severe consequences of osteoporosis are fractures [6] while the most severe outcomes of bone loss after fractures are secondary fractures [7–10].”
BackgroundGates, M., Pillay, J., Nuspl, M., Wingert, A., Vandermeer, B., & Hartling, L. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02181-w · Cited by 50
“The evidence for bisphosphonates as a class showed similar findings [48, 49, 211, 215].”
BackgroundResultInfluentialTian, N., Chen, D., Han, H., Jin, J., & Li, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-54192-9 · Cited by 47
Re-fracture and correlated risk factors in patients with osteoporotic vertebral fractures
Ma, X., Xia, H., Wang, J., Zhu, X., Huang, F., Lu, L., & He, L. (2018) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-018-0974-4 · Cited by 47
Ensrud, K. E., Kats, A. M., Boyd, C. M., Diem, S. J., Schousboe, J. T., Taylor, B. C., Bauer, D. C., Stone, K. L., & Langsetmo, L. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0682 · Cited by 47
Mammalian target of rapamycin as a therapeutic target in osteoporosis
Shen, G., Ren, H. J., Qiu, T., Zhang, Z., Zhao, W., Yu, X., Huang, J., Tang, J., Liang, D., Yao, Z., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26161 · Cited by 43
Sato, T., Castro, C. D., Yoon, S.-H., Zhao, Y., Greenlee, W. J., Weber, P. C., Viswanathan, U., Kulp, J. L., Brooks, D. J., Demay, M. B., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214396119 · Cited by 43
Polypharmacy in Osteoporosis Treatment
McConnell, M., & Shieh, A. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.05.011 · Cited by 42
Promoting mobility and healthy aging in men: a narrative review
Ebeling, P. R., Cicuttini, F., Scott, D. S., & Jones, G. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05080-w · Cited by 42
Metadata
- Authors
- Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians*
- Affiliations
- Yale University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-06-06
- Volume
- 166
- Issue
- 11
- Pages
- 818-839
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2614075773
- Cited by
- 676
- References
- 368
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 65 · 2023: 85 · 2022: 82 · 2021: 81 · 2020: 95 · 2019: 75 · 2018: 70 · 2017: 35
- FWCI
- 83.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteopenia, fracture prevention, pharmacotherapy, bisphosphonates, denosumab, zoledronic acid, risedronate, alendronate, hormone replacement therapy, raloxifene, calcium and vitamin D supplementation, treatment duration, hip fracture
- MeSH terms
- Denosumab, Bone Diseases, Metabolic, Calcium, Dietary, Diphosphonates, Female, Humans, Male, Osteoporosis, Risk Factors, Vitamin D, Exercise, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Teriparatide, Raloxifene Hydrochloride, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.